



Positive preclinical results in Xintela's glioblastoma project

Lund, Sweden, December 11, 2019 - Xintela AB (publ) announces positive preclinical results in the glioblastoma project. Xintela has developed function-blocking antibodies that bind to the company's target integrin $\alpha 10\beta 1$ and identified an antibody that suppresses the growth of glioblastoma tumors in a preclinical model.

In order to develop targeted antibody-based therapy for the aggressive brain tumor glioblastoma, Xintela is working on two parallel strategies, one using Antibody-Drug Conjugates (ADCs) in which a cell toxin is linked to an antibody and the other using antibodies that have their own function-blocking effect. Xintela previously reported that an ADC that binds to integrin $\alpha 10\beta 1$ on the glioblastoma cells has a killing effect on the cells both in cell studies and in an animal model and has published the results in the journal *Cancers* (2019, 11, 587). Now, Xintela is announcing that a function blocking antibody targeting integrin $\alpha 10\beta 1$ inhibits the function of glioblastoma cells including migration and significantly suppresses the growth of glioblastoma tumors in an animal model. This work has been carried out in collaboration with IVRS (In Vivo Research Services) in Lund, Sweden. Xintela has previously submitted a patent application covering the use of integrin $\alpha 10$ -antibodies for treatment of tumors in the CNS including glioblastoma.

"This is a huge milestone for our oncology project and our subsidiary Targinta. The positive results further validate our patent-protected target molecule integrin $\alpha 10\beta 1$ for the treatment of high-grade gliomas including glioblastoma. We have identified an antibody that has the potential to develop into a product for the treatment of glioblastoma and even other aggressive cancers", says Xintela's CEO Evy Lundgren-Åkerlund.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication on the 11th of December 2019.

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO
Tel: +46 70-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela is an innovator in the development of regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.